3rd quarter 2018 dsip list wells fargo advisors holdings portfolio OIVideo_TN Wealth Management Wells Fargo raises year-end S&P – wells fargo dsip ii fund – cyanacobalimin Frontiers | Mechanoregulation of Treatment Supply:90 mL (3 Bottles) — Approx. 120 Days | Continuity of Use

3rd quarter 2018 dsip list wells fargo advisors holdings portfolio OIVideo_TN Wealth Management Wells Fargo raises year-end S&P – wells fargo dsip ii fund – cyanacobalimin Frontiers | Mechanoregulation of Treatment Supply:90 mL (3 Bottles) — Approx. 120 Days | Continuity of Use

Frontiers | Mechanoregulation of Vascular Endothelial Growth Factor Receptor 2 in Angiogenesis

Kawashita, N

cyanacobalimin

Treatment Supply:90 mL (3 Bottles) — Approx. 120 Days | Continuity of Use

BPC-157 is not FDA approved and, since a 2023 FDA update, cannot be used as a bulk substance in 503A or 503B compounding pharmacies in the United States